Try Examples: Bifidobacterium adolescentis, Enterococcus faecalis, Acarbose, Caffeic acid, Oxaprozin, Obesity, Colorectal cancer


Accumulating evidence about the interaction between human microbiota and active substances, especially for those therapeutically-relevant substances such as clinical used drugs and traditional medicines/herbs, is deepenning our understanding in the role of "our second genome" in human health and diseases, and opens new avenue for managing/treating human healthy problems/diseases by manipulating microbiota-human interactions.

A centralized and standardized database to catalog Microbiota-Active Substance Interaction (MASI) will be very useful for related research fields, including microbiota-related precision medicine, pharmaceutical research, food and nutrition research, clinical pharmacy, health management studies. Here, the MASI database is developed to cater this urgent need by providing manually curated MASI data from scientific literature. ⨠ See More ...

MASI includes multiple interaction types as follows:


Microbe ---> Therapeutically-relevant Substance


Therapeutically-relevant Substance ---> Microbe


Diet ---> Microbe


Microbe --- Disease


Microbes have relative abundance landscape [8799 human gut microbiota samples from 3,465 patients (18 diseases) and 5,334 healthy individuals from 24 countries]

News & Updates

✅ Regularly update! [2020-06-30]

New records from latest literature will be curated and updated to the databbase regularly.

✅ MASI ver1.0 launched! [2020-06-30]

The MASI database was developed to catalog the interactions between microbiota species and active substances reported in scientific literature. Its first version contains:

  • 806 microbes
  • 46 probiotics
  • 1,074 Therapeutic substances [including 980 approved drugs]
  • 119 Herbal Substance
  • 103 Dietary Substance
  • 56 human disease, and
  • 11,215 interaction records

Page Views